- Life Molecular Imaging and PharmaLogic announce a partnership to manufacture and distribute Neuraceq from Cincinnati.
- Neuraceq is an imaging agent for Alzheimer’s diagnostics, expanding patient access in the Ohio region.
Life Molecular Imaging (LMI), a contract development and manufacturing organization has partnered with PharmaLogic Holdings Corp. to provide and distribute Neuraceq, an FDA-approved imaging agent for Alzheimer’s diagnostics, from PharmaLogic’s manufacturing site in Cincinnati, Ohio. This partnership aims to increase regional access to Neuraceq for patients needing diagnostic evaluation for Alzheimer’s disease and other cognitive disorders. The first doses were made available on October 24, 2024.
Neuraceq is a positron emission tomography (PET) imaging agent used to detect beta-amyloid plaques in the brains of adults with cognitive impairment, a diagnostic tool that helps assess treatment eligibility and supports enrollment in clinical trials. “Expanding Neuraceq manufacturing in Cincinnati, OH, in collaboration with PharmaLogic, further reinforces our commitment to meeting the increased market demand for patient access to amyloid PET imaging,” said Colleen Ruby, US Country Head, and Chief Operating Officer for Americas and APAC at Life Molecular Imaging.
The collaboration marks an important step in supporting new Alzheimer’s therapies in the Cincinnati area, where access to reliable beta-amyloid PET imaging is vital for patients and clinicians. James Beatty, VP of Development and Commercialization for PharmaLogic, noted, “Our collaboration with Life Molecular Imaging enhances our ability to support the adoption of newly approved novel therapies for Alzheimer’s disease by enabling broad and reliable access to beta-amyloid PET.”
Overview of outsourcing trends 
